Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
CLEO Diagnostics Ltd ( (AU:COV) ) has provided an update.
Cleo Diagnostics Ltd announced a successful A$5 million capital raise to support its U.S. commercial launch of the Pre-Surgical Ovarian Cancer Test and expedite the development of its mass ovarian cancer screening test. This funding introduces new institutional investors, endorsing CLEO’s technology and potential to address the urgent need for early cancer detection, with significant implications for its operations and industry positioning.
The most recent analyst rating on (AU:COV) stock is a Buy with a A$1.15 price target. To see the full list of analyst forecasts on CLEO Diagnostics Ltd stock, see the AU:COV Stock Forecast page.
More about CLEO Diagnostics Ltd
Cleo Diagnostics Ltd (ASX:COV) is an Australian medical technology company specializing in ovarian cancer diagnostics. The company is focused on developing blood tests for early detection of ovarian cancer, leveraging patented technology based on the CXCL10 biomarker. CLEO aims to address the critical need for earlier diagnosis of ovarian cancer, known for its high mortality rate, with a roadmap that includes pre-surgical tests, recurrence monitoring, and global screening solutions.
Average Trading Volume: 235,995
Technical Sentiment Signal: Buy
Current Market Cap: A$88.02M
For detailed information about COV stock, go to TipRanks’ Stock Analysis page.